PnuBioVax (PBV) / Sinopharm, ImmunoBiology - LARVOL DELTA

DEVELOPMENT OF A SEROTYPE 3 EXPERIMENTAL HUMAN PNEUMOCOCCAL CHALLENGE MODEL IN HEALTHY MALAWIAN ADULTS (ISPPD 2026) - "This model provides a critical platform for evaluating pneumococcal vaccine efficacy, particularly against serotype 3. Ongoing studies are employing this model to assess PnuBioVax, a protein-based vaccine, for its ability to prevent serotype 3 pneumococcal carriage."

Clinical • Infectious Disease • Pneumococcal Infections • Pneumonia